Earnings call transcript: Harmony Biosciences Q2 2025 beats EPS expectations

Harmony Biosciences Holdings (HRMY) reported Q2 2025 earnings, with an EPS of $0.92 significantly beating the $0.72 forecast, yet revenue of $200.5 million slightly missed expectations despite a 16% year-over-year increase. The stock reacted with a 3.88% pre-market decline, likely due to the revenue shortfall. The company reaffirmed its full-year revenue guidance, driven by continued strong performance of its core product Wakix, and highlighted key upcoming catalysts including Phase III data for ZYN-two in Fragile X syndrome and the initiation of Pitolacin HD Phase III trials, underscoring its robust, self-funded pipeline and $672 million cash position aimed at long-term growth.

Analysis

Harmony Biosciences (HRMY) presented a mixed financial picture in its Q2 2025 results, characterized by a significant earnings beat and a slight revenue shortfall. The company reported an EPS of $0.92, surpassing the $0.72 forecast by nearly 28%, yet its revenue of $200.5 million, despite representing 16% year-over-year growth, fell just short of the $204.59 million expectation. This top-line miss triggered a 3.88% pre-market stock decline, suggesting investor sensitivity to revenue momentum. Management attributed some of the discrepancy to a trade inventory drawdown, expressing confidence in future growth by reaffirming its full-year revenue guidance of $820-$860 million. The core business, anchored by the narcolepsy drug Wakix, remains robust, evidenced by the addition of 400 average patients and management's projection of it becoming a $1 billion-plus product. The central pillar of the investment thesis, however, is the company's late-stage pipeline. The most significant near-term catalyst is the upcoming top-line data from the Phase III RECONNECT trial for ZYN-two in Fragile X syndrome, which management has expressed high conviction in and could represent a transformational event as the first approved therapy for the condition. This is complemented by a broader pipeline, including next-generation pitolisant formulations (HD and GR) entering Phase III, a novel orexin-2 agonist, and EPX-100 for rare epilepsies, which collectively aim to generate peak sales of $3-6 billion. The company's financial position is exceptionally strong, with $672 million in cash and a profitable, self-funding operational model, providing substantial flexibility to advance its pipeline and pursue strategic business development.

Key Decisions for Investors

• The primary focus should be the imminent Q3 top-line data from the ZYN-two Phase III trial in Fragile X syndrome, which represents the most significant near-term catalyst and a binary event for the stock.
• Investors should monitor subsequent quarterly reports to verify that the Q2 revenue miss was an isolated incident related to inventory timing and that the underlying growth in Wakix patient additions remains strong.
• Given the company's profitability, $672 million cash position, and a broad late-stage pipeline, the post-earnings dip could be viewed as a buying opportunity for those with a long-term horizon, especially as the stock is noted to be undervalued by some metrics.
• It is crucial to weigh the potential upside from pipeline successes against the risks of clinical trial failures and future competition in the narcolepsy market from emerging orexin agonists.